FDA Cancels Proposed Rule On Clinical Trial Malfeasance
Executive Summary
US FDA has withdrawn a proposed rule that would have required sponsors to notify FDA if they became aware of data falsification during a clinical trial. Industry had been critical of the 2010 proposal.
You may also be interested in...
US FDA Shelves Proposal To Mandate Home-Use Device E-Labeling
A controversial 2016 proposed rule that would have required manufacturers of many class II and class III home-use devices to electronically submit device labeling information to US FDA will not be finalized, the agency affirmed in the Oct. 17 HHS Unified Agenda document. The agency also signaled plans to imminently finalize a broad device classification rule, and other updates.
US FDA's data falsification rule raises industry concerns
The US medtech industry has expressed serious concerns about a new rule proposed by the FDA, which, if finalised, would require device sponsors to report to the agency about any individual who is suspected of falsifying data in studies involving human or animal subjects.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.